The folly of faith in Pathological Complete Response to Neoadjuvant Chemotherapy for breast cancer скачать в хорошем качестве

The folly of faith in Pathological Complete Response to Neoadjuvant Chemotherapy for breast cancer

Presented for the Ronald Raven Prize session at the BASO~ACS Annual meeting London 6 Nov 2023 About Neoadjuvant chemotherapy: Listen to the latest talk- Neoadjuvant chemotherapy for breast cancer - Time to rethink. 27Jul22    • Neoadjuvant chemotherapy for breast cancer...   Original BMJ paper is at https://www.bmj.com/content/360/bmj.j... Full paper is available at http://discovery.ucl.ac.uk/10041365/ Full paper + Discussion is available at http://bit.ly/nactbmj2018full The BMJ Podcast   / neoadjuvant-treatment-for-breast-cancer-no...   Key messages Neoadjuvant chemotherapy is being increasingly used for breast cancer despite higher rates of local recurrence and no evidence of survival benefit, mainly because of the immediate and dramatic pathological responses seen with newer drugs The increased pathological response of the primary tumour in the breast does not translate into a survival benefit even when given in the adjuvant setting, challenging the paradigm of “window of opportunity” studies We must acknowledge that neoadjuvant chemotherapy may not be beneficial to breast cancer patients We should consider reducing the widespread use of neoadjuvant chemotherapy